Annals of Pancreatic Cancer最新文献

{"title":"From pancreatic cancer to lung cancer, ZIP4’s oncogenic function continues","authors":"Shi-Yong Sun","doi":"10.21037/apc-22-2","DOIUrl":"https://doi.org/10.21037/apc-22-2","url":null,"abstract":"","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81369166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transformation of metastatic nonfunctioning pancreatic neuroendocrine tumor into insulinoma—two case reports","authors":"Lawrence W. Wu, Syed M Qasim Hussaini, J. W. Lee, Daniel H Shu, R. Hruban, D. Laheru","doi":"10.21037/apc-22-1","DOIUrl":"https://doi.org/10.21037/apc-22-1","url":null,"abstract":"","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75545109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pancreatic neuroendocrine tumor in a 27-year-old patient with Cornelia de Lange syndrome: a case report","authors":"M. Wright, A. Kline, elliot k fishman, A. Javed","doi":"10.21037/apc-21-12","DOIUrl":"https://doi.org/10.21037/apc-21-12","url":null,"abstract":"","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79098482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EBF2 contributes to pancreatic cancer progenitor cell differentiation and tumor suppression","authors":"H. Mathew, J. Barb, S. Bentzen, Sheelu Varghese","doi":"10.21037/apc-21-17","DOIUrl":"https://doi.org/10.21037/apc-21-17","url":null,"abstract":"","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85890671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blood transfusion is associated with worse outcomes following pancreatic resection for pancreatic adenocarcinoma","authors":"A. Javed, S. Ronnekleiv-Kelly, A. Hasanain, M. Pflüger, J. Habib, M. Wright, Jin He, J. Cameron, elliot k fishman, S. Frank, M. Weiss, R. Burkhart","doi":"10.21037/apc-21-11","DOIUrl":"https://doi.org/10.21037/apc-21-11","url":null,"abstract":"","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83762461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Selected pre-operative factors which affect pancreaticoduodenectomy outcomes: a systematic review","authors":"T. Russell, P. Labib, S. Aroori","doi":"10.21037/apc-21-15","DOIUrl":"https://doi.org/10.21037/apc-21-15","url":null,"abstract":"","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75854576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A single-institutional analysis of racial disparities in clinicopathologic characteristics, treatment selections, and outcomes in advanced-stage pancreatic cancer patients.","authors":"Matthew Williams,&nbsp;Umut Özbek,&nbsp;Jung-Yi Lin,&nbsp;Celina Ang","doi":"10.21037/apc-21-5","DOIUrl":"https://doi.org/10.21037/apc-21-5","url":null,"abstract":"<p><strong>Background: </strong>To investigate racial disparities among unresectable/metastatic pancreatic ductal adenocarcinoma (PDA) patients treated with contemporary chemotherapy regimens at an urban center.</p><p><strong>Methods: </strong>Retrospective review of all PDA patients treated at a single institution between 2012-2017. Continuous and categorical variables were tested using <i>t</i>-test, Mann-Whitney U, chi-squared or Fisher's exact test as appropriate. Kaplan-Meier curves were generated and Cox proportional hazards models were used to analyze survival outcomes.</p><p><strong>Results: </strong>One hundred and forty-five patients identified as: White [69], African American (AA, 34), Asian [15], and Other [27]. Fifty-five-point-seven percent of patients received gemcitabine-based therapy <i>vs.</i> 36.6% received fluorouracil (5-FU) based therapy, specifically 26.1% received FOLFIRINOX and 43.7% received gemcitabine/nab-paclitaxel. In a univariable model, Asians had significantly worse overall survival (OS) than Whites [hazard ratio (HR) 2.74, P=0.013], but there were no OS differences between AA <i>vs.</i> Whites (HR 1.51, P=0.297) nor Other <i>vs.</i> Whites (HR 2.05, P=0.062). On multivariable analysis, Asians had worse OS compared to Whites (HR 2.62, P=0.018), and gemcitabine-based therapy was inferior to 5-FU-based therapy (HR 2.65, P=0.005). There were no OS differences between AA <i>vs</i>. Whites nor Other <i>vs</i>. Whites (HR 1.12, P=0.769 and HR 0.8, P=0.763, respectively).</p><p><strong>Conclusions: </strong>In this series of advanced PDA patients treated with contemporary chemotherapy, AA and White patients had comparable outcomes, but Asians had worse OS than White patients.</p>","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5f/aa/nihms-1753997.PMC8711781.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39771786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pancreatic adenocarcinoma in liver transplant recipients: a case series.","authors":"Muhammad A Rauf,&nbsp;Ioannis A Ziogas,&nbsp;Julia M Sealock,&nbsp;Lea K Davis,&nbsp;Manhal Izzy,&nbsp;Sophoclis P Alexopoulos,&nbsp;Lea K Matsuoka","doi":"10.21037/apc-21-4","DOIUrl":"https://doi.org/10.21037/apc-21-4","url":null,"abstract":"<p><strong>Background: </strong>Malignancy is one of the known leading causes of death among long-term liver transplantation (LT) survivors. Pancreatic cancer has an incidence of 7.6/100,000 in North America and constitutes a diagnostic challenge post-LT.</p><p><strong>Methods: </strong>This is a single-center, retrospective review of the electronic health records (EHRs) of LT recipients with pancreatic adenocarcinoma (1990-2019). The prevalence of pancreatic adenocarcinoma in our institutional non-LT population was assessed using an institutional de-identified database (Synthetic Derivative).</p><p><strong>Results: </strong>Six out of 2,232 (0.27%) LT recipients were diagnosed with pancreatic adenocarcinoma. Median age at diagnosis was 66.0 years (IQR, 57.8-71.8 years). Median time from LT to pancreatic adenocarcinoma diagnosis was 8.9 years (IQR, 4.7-16.2 years), the median size on imaging was 3.2 cm (IQR, 3.1-4.7 cm), and all tumors were located on the head of the pancreas. Three patients underwent surgical resection (one with adjuvant chemotherapy), two underwent palliative care, and one palliative chemotherapy with gemcitabine and abraxane. Over a median follow-up of 220.5 days (IQR, 144.8-399.5 days), all six patients died due to disease progression (100%). Pancreatic adenocarcinoma was diagnosed in 5,033 out of 2,484,772 (0.20%) individuals in the Synthetic Derivative.</p><p><strong>Conclusions: </strong>Our findings identified an increased incidence of pancreatic adenocarcinoma following LT compared to the general population.</p>","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/80/af/nihms-1753613.PMC8612297.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39660956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A national database analysis of acinar cell carcinoma of the pancreas, a histologically, epidemiologically, and biologically distinct entity increasing in incidence","authors":"J. Yonkus, J. Bergquist, R. Alva-Ruiz, T. Ivanics, E. Habermann, A. Abdelrahman, T. Grotz, S. Cleary, R. Smoot, D. Nagorney, M. Kendrick, T. Halfdanarson, M. Truty","doi":"10.21037/APC-21-1","DOIUrl":"https://doi.org/10.21037/APC-21-1","url":null,"abstract":"Background: Pancreatic acinar cell carcinoma is a rare exocrine malignancy that is distinct from pancreatic ductal adenocarcinoma. We sought to describe its changing incidence, compare its natural history to that of pancreatic ductal adenocarcinoma, and evaluate impact of treatment modalities using the National Cancer Data Base, and Surveillance Epidemiology and End Results datasets. Methods: Patients with histologically confirmed diagnosis were identified from the National Cancer Data Base and Surveillance Epidemiology and End Results. Parametric univariate analyses were performed to compare patient characteristics, tumor types and outcomes. Incidence trends were calculated using Surveillance Epidemiology and End Results data and unadjusted Kaplan-Meier Survival analysis was performed using data from the National Cancer Data Base. Results: Incidence of acinar cell carcinoma significantly increased by 73% over the study period compared to only 22% for ductal adenocarcinoma (P<0.01). Unadjusted and adjusted stage-specific survival was substantially superior for acinar cell carcinoma versus ductal adenocarcinoma in all stages. Pancreatic acinar cell carcinoma demonstrated lower age at diagnosis, larger and lower grade tumors, was less likely to demonstrate histopathologic lymphovascular invasion, and more likely to undergo curative-intent resection with lower positive margins compared to ductal adenocarcinoma. Amongst resected patients, ductal carcinoma histology remained the strongest independent predictor of increased mortality hazard compared to pancreatic acinar cell carcinoma. Conclusions: Acinar cell carcinoma is a less aggressive malignancy with a significantly rising incidence of unknown etiology and better overall survival in both unadjusted analysis and after adjustment for clinically relevant predictors of mortality. 10 surgical resection. These findings, along with the improved overall survival at all stages, suggests that PACC is a less aggressive malignancy than PDAC. The 73% increase in incidence over a 12 year study period is of significant interest. The study demonstrated that the incidence is increasing at a much faster rate than PDAC. The reason for the increasing incidence is unknown and is a subject for further investigation which should be followed with interval studies. Possible explanations for this increased incidence is improvements in the ability to identify this histologic subtype, increased incidental identification during abdominal imaging for other purposes, or due to genetic factors.","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89095110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Phase 1b clinical trial of LDE225 (Sonidegib) in combination with fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFIRINOX) in previously untreated locally advanced or metastatic pancreatic adenocarcinoma","authors":"J. Clark, N. Horick, Jill N. Allen, L. Blaszkowsky, Janet E. Murphy, C. Fuchs, B. Wolpin, R. Mayer, Jason E. Farris, J. Chan, K. Ng, N. McCleary, T. Abrams, D. Ryan, E. Kwak, T. Hong","doi":"10.21037/APC-20-41","DOIUrl":"https://doi.org/10.21037/APC-20-41","url":null,"abstract":"Harvard Medical School, Boston, MA, USA; Massachusetts General Hospital Cancer Center, Boston, MA, USA; Yale Cancer Center, New Haven, CT, USA; Dana Farber Cancer Institute, Boston, MA, USA; Dartmouth-Hitchcock Norris Cotton Cancer Center, One Medical Center Drive, Lebanon, NH, USA Contributions: (I) Conception and design: JW Clark, EL Kwak, TS Hong; (II) Administrative support: None; (III) Provision of study materials or patients: JW Clark, JN Allen, LS Blaszkowsky, JE Murphy, C Fuchs, BM Wolpin, RJ Mayer, JE Farris, JA Chan, K Ng, NJ McCleary, TA Abrams, DP Ryan, EL Kwak; (IV) Collection and assembly of data: JW Clark, N Horick, EL Kwak, TS Hong; (V) Data analysis and interpretation: JW Clark, N Horick, EL Kwak, TS Hong; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. These authors contributed equally to this work. Correspondence to: Jeffrey W. Clark, MD. Massachusetts General Hospital Cancer Center, 55 Fruit Street, 223 Bartlett Hall, Boston, MA 02114, USA. Email: clark.jeffrey@mgh.harvard.edu.","PeriodicalId":8372,"journal":{"name":"Annals of Pancreatic Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73462285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}